• Describe the risk factors associated with AFib and prevalence of asymptomatic AFib
• Identify key aspects of current recommendations on atrial fibrillation, anticoagulation, stroke risk, and prevention approaches
• Explain the key benefits of anticoagulation with newer oral anticoagulation agents
• Utilize anticoagulation administration safety protocols to decrease medication errors, decrease unwanted medication interactions, and availability of reversal agents

Kimberly Newlin, RN, CNS, ANP-C
Sutter Roseville Medical Center
Roseville, California

Laura VanBrocklin, DNP, FNP, RN-BC, FPCNA
Denver Health Medical Center & Hospital
Denver, Colorado

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of PCNA and TFF. The Preventative Cardiovascular Nurses Association (PCNA) is accredited by AANP as an approved provider of nurse practitioner continuing education. Provider number: 030602. This activity is approved for 1.0 contact hour(s) (which includes 0.35 hour(s) of pharmacology).

CREDIT DESIGNATION

Nurses

The France Foundation designates this activity for 1.00 nursing contact hour.

All other healthcare professionals completing this course will be issued a statement of participation.

DISCLOSURE POLICY
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Preventative Cardiovascular Nurses Association (PCNA) and The France Foundation (TFF) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial entity. PCNA and TFF resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs.

Furthermore, PCNA and TFF seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. PCNA and TFF are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Planning committee members, faculty, reviewers, and activity staff have disclosed the following relevant financial relationships. All relevant financial relationships listed have been mitigated.

PCNA and TFF require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling.

This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. PCNA and TFF do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

This activity is supported by an educational grant from Bristol Myers Squibb.

Copyright © 2023 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

• The materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.

• Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein) without The France Foundation's prior written permission